How do VKORC1 and CYP2C9 gene polymorphisms influence warfarin dosing and INR response?

• A. They do not affect warfarin dosing.
• B. They influence sensitivity to warfarin (VKORC1) and metabolism rate (CYP2C9); certain haplotypes require lower dosing; genotype-guided dosing can reduce extremes of INR.
• C. They only affect bleeding risk, not dosing.
• D. Genotyping is not clinically useful for warfarin management.

Answer: (B)

Warfarin response is driven by genetic factors that determine both how sensitive the body is to the drug and how quickly it is cleared. VKORC1 encodes the vitamin K epoxide reductase enzyme, the target of warfarin. Polymorphisms that reduce VKORC1 expression make the enzyme more sensitive to inhibition, so lower doses of warfarin are needed to achieve the same anticoagulant effect. CYP2C9 encodes the hepatic enzyme that metabolizes the more potent S-enantiomer of warfarin. Variants that reduce CYP2C9 activity slow metabolism, leading to higher circulating levels for a given dose and a greater risk of bleeding; these patients often require smaller, slower dose increases. Together, these genetic differences explain a substantial portion of the variability in dose requirements and INR responses among individuals.

Using genotype information to guide starting and maintenance dosing—often referred to as genotype-guided dosing—helps tailor therapy to the individual, aiming to reach a therapeutic INR more quickly and to minimize extreme INRs that raise bleeding risk or risk of under-anticoagulation. While other factors like age, weight, diet, and drug interactions matter, the combined VKORC1 and CYP2C9 profile provides valuable, actionable guidance for warfarin management.

The other statements are less accurate because these genes do influence dosing, not just bleeding risk, and genotyping has demonstrated clinical usefulness in guiding warfarin therapy.